antibody-drug conjugate program (Shangai Pharma Biotherapeutics)

N/A

Report date: 2025/03/14 16:37:17

Base Information

Drug Nameantibody-drug conjugate program (Shangai Pharma Biotherapeutics)
Drug Alias NameADCs (Shanghai Pharma Biotherapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsMetastatic breast cancerLymphoma, Large-Cell, AnaplasticHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Pharma Biotherapeutics USA Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Pharma Biotherapeutics USA Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerLymphoma, Large-Cell, AnaplasticHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A